Biotech · Public company · Seattle, WA, US
Perspective Therapeutics, Inc.
Ticker CATX · SEC CIK 0000728387
Track this companyFree. Adds Perspective Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials65 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline9
- [203Pb]Pb-PSV359Phase 2 · Pancreatic Ductal AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- [203Pb]VMT-α-NETPhase 2 · Neuroendocrine Tumors UnresectableClinicalTrials.gov · fetched Nov 12, 2026
- [203Pb]VMT01Phase 2 · Recurrent Melanoma (Skin)ClinicalTrials.gov · fetched Nov 12, 2026
- [212Pb]Pb-PSV359Phase 2 · Pancreatic Ductal AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- [212Pb]VMT-α-NETPhase 2 · Neuroendocrine Tumors UnresectableClinicalTrials.gov · fetched Nov 12, 2026
- [212Pb]VMT01Phase 2 · Recurrent Melanoma (Skin)ClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 2 · Recurrent Melanoma (Skin)ClinicalTrials.gov · fetched Nov 12, 2026
- [203Pb]VMT01Phase 1 · Melanoma (Skin)ClinicalTrials.gov · fetched Nov 12, 2026
- [68Ga]VMT02Phase 1 · Melanoma (Skin)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Lead-212 PSV359 Therapy for Patients With Solid TumorsPHASE1_PHASE2 · RECRUITING · started Apr 28, 2025ClinicalTrials.gov NCT06710756 · fetched Nov 12, 2026
- A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine TumorsEARLY_PHASE1 · ACTIVE_NOT_RECRUITING · started Nov 10, 2023ClinicalTrials.gov NCT06148636 · fetched Nov 12, 2026
- Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive TumorsPHASE1_PHASE2 · RECRUITING · started Sep 27, 2023ClinicalTrials.gov NCT05636618 · fetched Nov 12, 2026
- MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced MelanomaPHASE1_PHASE2 · RECRUITING · started Jun 1, 2023ClinicalTrials.gov NCT05655312 · fetched Nov 12, 2026
- A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging AgentEARLY_PHASE1 · ACTIVE_NOT_RECRUITING · started Aug 22, 2022ClinicalTrials.gov NCT05111509 · fetched Nov 12, 2026
- Targeted Imaging of Melanoma for Alpha-Particle RadiotherapyPHASE1 · COMPLETED · started Mar 5, 2021ClinicalTrials.gov NCT04904120 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 23, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 8, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 1, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 8, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 3, 2026 · fetched Nov 12, 2026